Literature DB >> 7919385

PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma.

F Bosch1, P Jares, E Campo, A Lopez-Guillermo, M A Piris, N Villamor, D Tassies, E S Jaffe, E Montserrat, C Rozman.   

Abstract

The t(11;14)(q13;q32) translocation and its molecular counterpart bcl-1 rearrangement are frequently associated with mantle cell lymphomas (MCLs) and only occasionally with other variants of B-cell lymphoid malignancies. This translocation seems to activate the expression of PRAD-1/cyclin D1 gene located downstream from the major breakpoint cluster region of this rearrangement. However, the possible overexpression of this gene in other lymphoproliferative disorders independently of bcl-1 rearrangement is unknown. We have examined the overexpression of PRAD-1 gene in a large series of 142 lymphoproliferative disorders including 20 MCLs by Northern blot analysis. Cytogenetic and/or bcl-1 rearrangement analysis with 2 probes (MTC, p94PS) were performed in 28 cases. Strong PRAD-1 overexpression was observed in 19 of the 20 MCLs including 3 gastrointestinal forms and 4 blastic variants. t(11;14) and/or bcl-1 rearrangement was detected in 6 of the 12 MCLs examined. No correlation was found between the different levels of mRNA expression and the pathologic characteristics of the lymphoma. Among chronic lymphoproliferative disorders other than MCL, only 1 atypical chronic lymphocytic leukemia (CLL) with a t(11;14) translocation and bcl-1 rearrangement and the 2 hairy cell leukemias (HCLs) analyzed showed upregulation of PRAD-1 gene. The expression in the 2 HCLs was lower than in MCL, and no bcl-1 rearrangement was observed. These findings indicate that PRAD-1 overexpression is a highly sensitive and specific molecular marker of MCL but it may also be upregulated in some B-CLLs and in HCL.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7919385

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  55 in total

Review 1.  Molecular diagnostic approach to non-Hodgkin's lymphoma.

Authors:  D A Arber
Journal:  J Mol Diagn       Date:  2000-11       Impact factor: 5.568

2.  Mantle cell lymphoma is characterized by inactivation of the ATM gene.

Authors:  C Schaffner; I Idler; S Stilgenbauer; H Döhner; P Lichter
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

3.  The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.

Authors:  Julia Slotta-Huspenina; Ina Koch; Laurence de Leval; Gisela Keller; Margit Klier; Karin Bink; Marcus Kremer; Mark Raffeld; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

4.  RhoGTPases and p53 are involved in the morphological appearance and interferon-alpha response of hairy cells.

Authors:  Benjamin Chaigne-Delalande; Lynda Deuve; Edith Reuzeau; Caroline Basoni; David Lafarge; Christine Varon; Florence Tatin; Guerric Anies; Richard Garand; Ijsbrand Kramer; Elisabeth Génot
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

5.  Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting.

Authors:  Antonina V Kurtova; Archito T Tamayo; Richard J Ford; Jan A Burger
Journal:  Blood       Date:  2009-02-19       Impact factor: 22.113

Review 6.  Novel agents in mantle cell lymphoma.

Authors:  Anita Kumar
Journal:  Curr Oncol Rep       Date:  2015-08       Impact factor: 5.075

Review 7.  Genetic abnormalities in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia.

Authors:  M Merup
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

Review 8.  Low-grade lymphomas: new entities and treatment concepts.

Authors:  F B Hagemeister
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

9.  Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation.

Authors:  C Chalermrujinanant; W Michowski; G Sittithumcharee; F Esashi; S Jirawatnotai
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

Review 10.  Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.

Authors:  Kevin Wang; Xiangao Huang; Maurizio Di Liberto; Selina Chen-Kiang
Journal:  Hematol Oncol Clin North Am       Date:  2020-08-01       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.